Adjuvant Capecitabine, Docetaxel, Cyclophosphamide, and Epirubicin for Early Breast Cancer: Final Analysis of the Randomized FinXX TrialHeikki Joensuu, Henrik Lindman, R. Asola et al.|Journal of Clinical Oncology|2011Cited by 118
Adjuvant Capecitabine in Combination With Docetaxel, Epirubicin, and Cyclophosphamide for Early Breast CancerHeikki Joensuu, Henrik Lindman, Pirkko‐Liisa Kellokumpu‐Lehtinen et al.|JAMA Oncology|2017Cited by 95
Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trialHeikki Joensuu, Henrik Lindman, Pirkko‐Liisa Kellokumpu‐Lehtinen et al.|The Lancet Oncology|2009Cited by 65
Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX)Heikki Joensuu, Henrik Lindman, Pirkko‐Liisa Kellokumpu‐Lehtinen et al.|Acta Oncologica|2013Cited by 24
Adjuvant capesitabine in combination with docetaxel (T), epirubicin (E), and cyclophosphamide (C) in the treatment of early breast cancer (BC): 10-year survival results from the randomized FinXX trial.Heikki Joensuu, Henrik Lindman, Pirkko‐Liisa Kellokumpu‐Lehtinen et al.|Journal of Clinical Oncology|2016Cited by 10